- Network with senior biopharma, life sciences and business leaders who are transforming research and development
- 75% of in-person attendees in 2024 were CEO, Managing Director, VP or Director level meaning you are amongst true decision-makers
- Establish new relationships and build on existing ones through informal drinks receptions, networking lunches and coffee breaks
- Kickstart new business deals ahead of time using the networking app
Global Pharma and Biotech Summit
Biopharmaceutical businesses are striving to innovate and achieve growth amid relentless disruption. Breakthroughs in precision medicine and obesity treatments are reshaping healthcare. AI is predicted to drive discovery of 30 percent of new drugs this year. Industry leaders and start-ups are collaborating and competing to develop the next blockbuster. But sustainable growth is threatened by factors such as regulatory divergence, overburdened health systems and geopolitical risk.
The Global Pharma and Biotech Summit is the essential event for you to explore era-defining trends and developments in healthcare and life sciences. Distinguished innovators, investors and C-suite executives will discuss what’s new in key areas such as drug discovery, clinical trials, market access and patient engagement.
Life sciences leaders include
Why Attend?
Understand
the technology and innovation behind new treatments with the power to transform healthcare.
Connect
with industry leaders responsible for the big decisions in areas such as investment, innovation and market access.
Discover
new ideas to support business transformation and maximise return on investment.
Key themes
Geopolitical and Economic Disruptions:
The escalating political and economic tension between the US and China raises concerns about strategic de-coupling, affecting global R&D, manufacturing, and market access.
The Rise of New Pharma Powers:
India is recognised as a rapidly growing biotech hub, maturing beyond generic drugs and China is transitioning from a licensing market to a global innovation force.
Regulation of Emerging Technologies:
Regulators face challenges assessing complex technologies with limited transparency. Defining "evidence" in the context of AI and RWE is also a concern.
Drug Pricing and Reimbursement Pressures:
Balancing drug affordability with the need to fund innovation is a central challenge.
Patient Empowerment and Digital Health:
Apps, sensors, and digital platforms are reshaping patient interactions with therapies.
What's on the agenda, networking and which speakers will be there:
Connect with Life Sciences Leaders
Supporting Partners
Upcoming Events we think you'll enjoy:
Endpoints News Post Hoc Live:
The View from the UK - with the FT's Hannah Kuchler
4 November 2025 | 11 AM ET | Online
Free Webinar
"I learned so much. We heard from practising doctors, government payers... Putting that spectrum together has been incredibly educational for me and really helpful for our practice"
- Seth Ettenberg, President and CEO, BlueRock Therapeutics
Join our mailing list
Stay up to date with the latest news, events and offers from FT Live.
Get in touch
Speaking Opportunities
Ciaran Larkin
ciaran.larkin@ft.com
Sponsorship
Holly Watson-Steward
holly.watson-steward@ft.com
Delegate Services
Hauwra Sharif
hauwra.sharif@ft.com
© Financial Times Live
FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice
